Adocia SA announced the final approval by the German (BfArM) regulatory authorities to conduct three clinical studies on BioChaperone® Combo. Tonghua Dongbao is financing the entire program which will be conducted by Adocia, with no impact on Adocia's cash in hand. Adocia has demonstrated the clinical benefits of this new combination, notably the reduction of hyperglycemia and hypoglycemia compared to "premix" insulins (insulin with both a rapid-acting and long-acting profile), while maintaining the simplicity of use of a single injection.
Market Closed -
Other stock markets
|
After market 11:55:23 am | |||
9.08 EUR | -1.41% | 9.09 | +0.11% |
May. 14 | Adocia SA announced that it has received ?2 million in funding | CI |
Apr. 24 | Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.32% | 144M | |
+11.08% | 115B | |
+12.64% | 106B | |
-4.33% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-11.79% | 17.56B | |
-40.50% | 17.32B | |
+7.38% | 14.03B | |
+32.93% | 12.13B |
- Stock Market
- Equities
- ADOC Stock
- News Adocia
- Adocia SA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao